Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

TARLATAMAB: 145 Adverse Event Reports & Safety Profile

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now
145
Total FAERS Reports
49 (33.8%)
Deaths Reported
52
Hospitalizations
145
As Primary/Secondary Suspect
6
Life-Threatening

First Report: 20230420 · Latest Report: 20250715

What Are the Most Common TARLATAMAB Side Effects?

#1 Most Reported
Cytokine release syndrome
59 reports (40.7%)
#2 Most Reported
Death
31 reports (21.4%)
#3 Most Reported
Immune effector cell-associated neurotoxicity syndrome
30 reports (20.7%)

All TARLATAMAB Side Effects by Frequency

Side Effect Reports % of Total Deaths Hosp.
Cytokine release syndrome 59 40.7% 11 32
Death 31 21.4% 31 5
Immune effector cell-associated neurotoxicity syndrome 30 20.7% 6 15
Off label use 14 9.7% 2 6
Disease progression 11 7.6% 6 3
Small cell lung cancer 10 6.9% 3 2
Metastases to central nervous system 7 4.8% 2 2
Therapy partial responder 7 4.8% 4 3
Pyrexia 6 4.1% 2 3
Dysgeusia 5 3.5% 1 2
Hypotension 5 3.5% 1 4

Who Reports TARLATAMAB Side Effects? Age & Gender Data

Gender: 34.0% female, 66.0% male. Average age: 62.7 years. Most reports from: US. View detailed demographics →

Is TARLATAMAB Getting Safer? Reports by Year

YearReportsDeathsHosp.
2023 2 0 2
2024 32 9 18
2025 28 9 15

View full timeline →

What Is TARLATAMAB Used For?

IndicationReports
Small cell lung cancer 73
Small cell lung cancer extensive stage 33
Product used for unknown indication 9
Small cell carcinoma 5

TARLATAMAB vs Alternatives: Which Is Safer?

TARLATAMAB vs TARLATAMAB-DLLE TARLATAMAB vs TASIGNA TARLATAMAB vs TASIMELTEON TARLATAMAB vs TAVABOROLE TARLATAMAB vs TAXOL TARLATAMAB vs TAXOTERE TARLATAMAB vs TAZAROTENE TARLATAMAB vs TAZEMETOSTAT TARLATAMAB vs TAZEMETOSTAT HYDROBROMIDE TARLATAMAB vs TAZOBACTAM

Official FDA Label for TARLATAMAB

Official prescribing information from the FDA-approved drug label.